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Abstract
Introduction:	Neoplastic	pericardial	effusion	(NPE)	represents	a common	cause	of	morbidity	and	mortality	in	patients	with	cancer.	NPE	
presents	frequently	as	cardiac	tamponade,	requiring	urgent	pericardiocentesis	or	pericardiotomy,	with	subsequent	pericardial	fluid	draina-
ge.	Despite	high	effectiveness	of	such	procedures,	the	recurrence	of	effusion	is	noted	in	30-	60%	of	patients.	Intrapericardial	therapy	with	
cisplatin	was	found	to	be	effective	in	NPE	due	to	lung	and	breast	cancer.	Its	role	in	cardiac	tamponade	due	to	renal	cancer	is	unknown.	
Case presentation: We	presented	an	82-year-old	man	with	renal	cancer	who	was	admitted	to	the	Intensive	Care	Unit	because	
of	threatening	pericardial	tamponade	due	to	NPE.	
Urgent	subxiphoid	pericardiotomy	was	performed	with	subsequent	evacuation	of	1000	ml	of	bloody	fluid.	On	the	inner	surface	
of	the	pericardium,	several	pink	nodules	were	found.	Histological	examination	revealed	carcinoma	clarocellulare.	In	view	of	the	
persistent	high	drainage	of	the	pericardium,	intrapericardial	cisplatin	therapy	was	performed.	On	the	first	day	after	surgery,	col-
chicine	0.5	mg/day/po	was	also	introduced.	No	side	effects	of	the	treatment	were	observed.	The	patient	died	12	months	later	
due	to	cancer	progression	and	cachexia.	No	recurrence	of	pericardial	effusion	was	observed.	
Conclusion: This	is	the	first	case	study	demonstrating	long-term	efficacy	and	safety	of	intrapericardial	cisplatin	combined	with	
oral	colchicine	in	NPE	due	to	metastatic	renal	cell	carcinoma.	
Key words: neoplastic	pericardial	effusion,	renal	cancer,	cisplatin,	intrapericardial	treatment,	colchicine
Adv Respir Med. 2018; 86: 197–201
Introduction
Neoplastic pericardial effusion (NPE) rep-
resents a common cause of morbidity and mortality 
in cancer patients. Over 60% of NPE is diagnosed in 
the course of lung cancer, breast cancer and hema-
tologic malignancies [1–3]. NPE presents frequently 
as cardiac tamponade, requiring urgent pericar-
diocentesis or pericardiotomy, with subsequent 
pericardial  fluid (PF) drainage [4, 5]. Despite high 
effectiveness of such procedures, the recurrence 
of effusion was noted in 30–60% of patients [6, 7]. 
Intrapericardial cisplatin therapy was found 
to be an effective method of prevention of NPE 
recurrence in lung cancer patients [8, 9]. The 
efficacy of such treatment in other solid tumors 
is poorly documented. 
Colchicine, an anti-inflammatory drug, inhib-
its neutrophils motility and activity at the site of 
inflammation, decreases the production of IL-1 by 
monocytes and reduces the release of lysozymes 
by phagocytes [10]. It is currently recommended 
as first-line therapy of acute and recurrent benign 
pericarditis [4]. The COPPS study proved colchi-
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Figure 1.	Chest	X-ray:	significantly	enlarged	cardiac	silhouette,	bila-
teral	pleural	effusion,	and	bilateral	lung	infiltrative	lesions,	suggesting	
metastatic	lung	disease
Figure 2.	ECG	Sinus	rhythm	about	85	per	minute.	Left	axis	pathological.	Left	anterior	hemiblock.	Right	bundle	branch	block.	Electrical	alternans
cine efficacy in prevention of post-pericardiotomy 
syndrome [11]. The role of colchicine in NPE has 
not been established yet.
The present case report concerns successful 
intra-pericardial cisplatin treatment combined 
with oral colchicine therapy in the patient with 
NPE due to metastatic renal cancer. 
Case presentation
An 82-year-old man, treated for arterial hy-
pertension and hypothyroidism, with a history of 
right-sided nephrectomy in 2003 due to clear-cell 
renal carcinoma, with metastatic lung disease tre-
ated with sunitinib (2009–2012) and everolimus 
(2012–2013) was admitted to the Intensive Care 
Unit (ICU) in June 2013 because of threatening 
cardiac tamponade.  Two weeks earlier the patient 
had noticed a decrease in exercise tolerance, ac-
companied by a dry cough. 
On admission to ICU the man was in poor 
general condition, with marked weight loss about 
5 kg in 3 months (BMI 18). Physical examination 
revealed blood pressure 150/80, heart rate 90/min. 
On auscultation — dull heart sounds, and wheezing 
over the lung fields were heard. Liver was enlarged, 
palpable 4 cm below the right costal margin. Ortop-
nea and hemodynamic instability were not found. 
Laboratory analysis revealed anemia (E 3.85 
× 1012/l, hemoglobin 9.4 g%), elevated levels of 
D-dimer (2674 ug/l), increased GGTP (95 U/l) and 
NT-proBNP (541 pg/ml). TSH was 2.6 mIU/ml, 
fT4 — 17.8 pmol/l (within normal limits).
Chest X-ray showed significantly enlarged 
cardiac silhouette, bilateral pleural effusion, 
and bilateral lung infiltrative lesions, suggesting 
metastatic lung disease (Fig. 1).
ECG revealed sinus rhythm of about 85/min., 
left anterior hemi block, right branch bundle 
block. Low QRS voltage as well as signs of elec-
trical alternans were also recorded (Fig. 2).
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Figure 3.	Echocardiography	pre-	 treatment:	fluid	around	the	whole	
heart	(arrow)
Figure 4.	Echocardiography	post-	treatment:	no	fluid	around	the	pe-
ricardium	(arrow)
Figure 5.	Control	chest	X-ray	examination	revealed	the	decrease	of	
cardiac	dimensions	and	partial	regression	of	pleural	fluid
Bedside echocardiography demonstrated the 
presence of pericardial fluid (a layer of 9–16 mm), 
with elements of fibrin, surrounding the whole 
heart. Moreover, right atrium diastolic collapse 
was noted (Fig. 3).
Threatening cardiac tamponade was diagno-
sed. As the amount of fluid was not very large 
and the widest layer was found over the right 
ventricle, the patient was proposed subxiphoid 
pericardiotomy, but he was initially reluctant. 
 On the second day he experienced an episo-
de of atrial fibrillation with a decrease in blood 
pressure to 90/60 mm Hg. Urgent subxiphoid 
pericardiotomy was performed, 1000 ml of blo-
ody fluid was removed. Several pink nodules 
were found on the inner surface of pericardium. 
Histological examination of pericardial specimen 
revealed multiple carcinoma cell clusters — Ca 
clarocellulare. Pericardial fluid cytological exa-
mination was positive. Pericardial fluid cultures 
were negative. Thus NPE was confirmed. 
Due to persistent high pericardial drainage 
in subsequent days (250–450 ml of bloody fluid/ 
/day), intrapericardial cisplatin therapy was com-
menced. The drug was given on 5 consecutive 
days. Each dose consisted of 10 mg of cisplatin 
dissolved in 20 ml of 0.9% NaCl administered 
by a catheter into the pericardial sac. The drain 
was clamped for 24 hours, then the fluid was 
removed and the dose of cisplatin was repeated. 
Starting from the first day after surgery, colchicine 
0.5 mg/day was introduced. No complications of 
treatment were observed. 
Control echocardiographic examination con-
firmed significant resolution of PF. No signs of pe-
ricardial constriction were found (Fig. 4). Control 
chest X-ray examination disclosed the decrease 
of cardiac dimensions and partial regression of 
pleural fluid (Fig. 5).
On the 13th postoperative day pericardial drain 
was removed. The patient was discharged, and he 
continued the treatment with colchicine. Despite 
gradual progression of renal cell carcinoma, peri-
cardial disease has been well controlled until de-
ath. Last echocardiographic examination revealed 
the presence of additional echoes in the left atrium 
and left ventricle, representing probably intra-
cardiac metastatic lesions. The patient survived 
12 months from intrapericardial cisplatin therapy. 
Discussion
The ideal treatment for NPE ensures the 
complete removal of fluid, relief of symptoms, 
prevention of recurrent effusion, influence on the 
local neoplastic disease and survival benefit [12].
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Pericardiotomy with PF drainage was not 
a sufficient method of therapy in the presented 
patient due to subsequent large daily production 
of PF. 
Improvement of local disease control and 
prevention of PF recurrence may be achieved by 
intrapericardial instillation of cytotoxic agents 
such as cisplatin, thiotepa, bleomycin [8, 9, 
13–16]. Recently, intrapericardial activity of anti-
-angiogenic factor — bevacizumab was reported 
in NPE [17]. 
The rationale for intrapericardial instillation 
of antineoplastic drug is to provide its higher con-
centration than those achieved in the course of 
systemic therapy. So far no randomized controlled 
trials evaluating the efficacy and safety of intra-
pericardial chemotherapy have been performed, 
and that is why all recommendations are based 
only on the results of small observational studies.
Intrapericardial treatment tailored to the 
type of the tumor indicate that administration of 
cisplatin has been most efficient in NPE due to 
lung cancer [8, 9, 13], and intrapericardial instil-
lation of thiotepa has been more effective in NPE 
due to breast cancer [18, 19]. 
There is no evidence for the efficacy of sys-
temic chemotherapy with cisplatin in patients 
with renal cell carcinoma, and the experience 
with intrapericardial therapy in this type of 
tumor is lacking. Nevertheless, we decided to 
apply intrapericardial cisplatin, having in mind 
its good therapeutic and safety profile in other 
solid tumors. 
Colchicine was introduced as an early add
-on therapy to improve local anti-inflammatory 
effect. There is not much data concerning col-
chicine therapy in NPE. Ng et al. [20] reported 
successful colchicine use in NPE that developed 
in the course of malignant myeloma [20]. In this 
patient, pericardiocentesis, followed by surgical 
approach with the creation of pericardial window, 
were ineffective. Colchicine at a dose of 1 mg/
day, stopped pericardial drainage after 5 days of 
treatment. 
In our patient intrapericardial cisplatin ad-
ministration and colchicine therapy resulted in 
gradual, almost complete resolution of pericardial 
fluid. Moreover, prolonged colchicine therapy 
successfully prevented effusion recurrence for 
the next 12 months. 
No side effects of colchicine treatment were 
observed in our patient. Prolonged colchicine the-
rapy has been well tolerated in patients with other 
diseases such as familial Mediterranean fever or 
in recurrent benign pericarditis [21, 22]. Never-
theless, it is important to adjust the daily dose of 
the drug to the patient’s age and weight [4]. The 
dose of colchicine was reduced in our patient to 
0.5 mg/d, due to low weight and advanced age. 
Drug interactions have to be taken into con-
sideration in the course of prolonged colchicine 
use, especially with macrolides and statins [4]. 
The interaction between TKI-inhibitors and col-
chicines has been also reported, thus lowering its 
dose to 0.3 mg/day was proposed [23]. 
Summary
Intrapericardial cisplatin therapy combined 
with oral colchicine demonstrated an excellent 
and prolonged local anti-inflammatory effect in 
cardiac tamponade due to metastatic renal cell 
carcinoma. 
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